Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has executed a $15 million working capital loan agreement with Hercules Technology Growth Capital. The funds available under the loan will be used for capital equipment and working capital purposes. In connection with the loan, Alexza issued Hercules warrants to purchase 376,394 shares of common stock at an exercise price of $2.69 per share, which was the 50-day average daily weighted average trading price at the time the term sheet for the loan was issued by Hercules.
"We are very pleased to secure this working capital financing," said August J. Moretti, Senior Vice President and CFO of Alexza. "This loan is an important piece of our corporate finance strategy at Alexza. The proceeds will extend our operating runway as we undertake the transition to commercialization of our lead product candidate, AZ-004 (Staccato loxapine) which has a PDUFA goal date of October 11, 2010."
Early RSV vaccination in pregnancy provides best protection for newborns